

Supplementary Table 1. Univariate Cox proportional hazard analyses for all clinical variables considered in this study.

REF: reference group

Variable		N	Locoregional Regression		Mortality		Progression		Distant Metastasis	
			HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age at diagnosis	≥65	55	0.749 (0.38-1.47)	0,4	1.176 (0.77-1.8)	0,45	0.984 (0.65-1.49)	0,94	0.844 (0.4-1.78)	0,66
	<65	142	REF		REF		REF		REF	
Sex	female	55	0.515 (0.25-1.06)	0,072	0.65 (0.42-1.01)	0,055	0.729 (0.48-1.1)	0,13	0.334 (0.13-0.85)	0,022
	male	142	REF		REF		REF		REF	
Alcohol	no	22	1.235 (0.52-2.95)	0,64	0.769 (0.4-1.49)	0,44	0.813 (0.43-1.52)	0,52	0.243 (0.03-1.79)	0,17
	former alcoholic	22	2.158 (1.03-4.52)	0,041	1.76 (1.05-2.95)	0,032	1.59 (0.95-2.66)	0,076	2.68 (1.25-5.73)	0,011
	yes	146	REF		REF		REF		REF	
	missing	7								
Tobacco	never	5	0 (0-Inf)	1	0.724 (0.18-2.94)	0,65	0.575 (0.14-2.33)	0,44	0 (0-Inf)	1
	former smoker	30	0.463 (0.17-1.29)	0,14	0.657 (0.37-1.16)	0,15	0.594 (0.34-1.05)	0,071	0.65 (0.23-1.83)	0,42
	yes	156	REF		REF		REF		REF	
	missing	6								
Tumour subsite	Larynx	34	1.47 (0.73-2.96)	0,28	0.615 (0.35-1.09)	0,094	0.822 (0.49-1.38)	0,46	1.026 (0.47-2.25)	0,95
	Hypopharynx	78	0.708 (0.37-1.37)	0,3	0.517 (0.34-0.78)	0,0017	0.555 (0.37-0.83)	0,0039	0.436 (0.2-0.93)	0,032
	Oropharynx	85								
Tumour volume	≥25.4 cc	70	1.754 (0.96-3.19)	0,066	2.147 (1.42-3.24)	0,00027	1.832 (1.23-2.72)	0,0027	1.513 (0.76-3)	0,23
	<25.4 cc	96	REF		REF		REF		REF	
	missing	31								
Stage	IVB	20	0.896 (0.35-2.28)	0,82	1.803 (1.06-3.06)	0,029	1.438 (0.85-2.42)	0,17	2.093 (0.95-4.6)	0,066
	III	40	0.443 (0.19-1.05)	0,064	0.607 (0.36-1.03)	0,063	0.521 (0.31-0.88)	0,014	0.306 (0.09-1.01)	0,051
	II	2	0 (0-Inf)	1	1.133 (0.16-8.17)	0,9	0.819 (0.11-5.9)	0,84	0 (0-Inf)	1
	IVA	135	REF		REF		REF		REF	
Cumulative cisplatin dose	<200mg/cm2	67	2.569 (1.45-4.56)	0,0012	1.737 (1.18-2.55)	0,0049	1.704 (1.18-2.47)	0,0048	1.175 (0.6-2.29)	0,64
	≥200mg/cm2	126	REF		REF		REF		REF	
	missing	4								